## Supplementary Data

SUPPLEMENTARY FIG. S1. Effects of MAO inhibition on mitochondrial or cytosolic oxidative status. (A) Cytosolic  $H_2O_2$  formation measured by Cyto-HyPer in isolated NRVMs treated with 0.5  $\mu$ M doxorubicin for 24 h, in the presence or absence of 100  $\mu$ M pargyline. Cells have been further stimulated with increasing concentrations of H<sub>2</sub>O<sub>2</sub> (i.e., 1–10–100  $\mu$ M) for 10 min. p < 0.001 versus Basal by one-way ANOVA with post hoc Tukey's multiple comparison test. (B) Western blot representing the efficiency of different concentrations of MAO-A siRNA (i.e., 20-40-60 pmol) compared with scramble (Scr) in NRVMs. (C) GSSG/GSH ratio measured in isolated NRVMs treated with  $0.5 \,\mu M$  doxorubicin for 24 h, in the presence or absence of  $100 \,\mu M$  pargyline. \* $p < 0.05 \,versus$  Untreated, \* $p < 0.05 \,versus$  Doxo by one-way ANOVA with *post hoc* Tukey's multiple comparison test. (D) Total thiol oxidation status in isolated NRVMs treated with 0.5  $\mu$ M doxorubicin for 24 h, in the presence or absence of 100  $\mu$ M pargyline. (E) AMVMs treated with 0.5  $\mu$ M doxorubicin for 24 h, in the presence or absence of  $200 \,\mu M$  pargyline. In all conditions, cells were treated with  $100 \,\mu M$  of H<sub>2</sub>O<sub>2</sub> for 10 min, and rod-shaped AMVMs have been quantified. \*p < 0.001 versus Untreated, \*p < 0.001 versus Doxo by one-way ANOVA with post hoc Tukey's multiple comparison test. (F) Western blot representing the expression level of MAO-A in NRVMs treated with or without  $0.5 \,\mu M$ doxorubicin for 24 h. The expression level of MAO-A has been analyzed by densitometry analysis and normalized to actin. (G) Western blot representing the expression level of MAO-B in AMVMs treated with or without  $0.5 \,\mu M$  doxorubicin for 24 h. The expression level of MAO-A has been analyzed by densitometry analysis and normalized to actin. (H) Mitochondrial  $H_2O_2$ formation measured by Mito-HyPer in isolated NRVMs treated with  $0.5 \,\mu M$  doxorubicin for 24 h, in the presence or absence of  $100 \,\mu M$  pargyline. Cells have been further stimulated with  $20 \,\mu M$  tyramine for 2 h. \*p < 0.05 versus Untreated Vehicle, \*p < 0.001 versus Untreated Tyramine, \*p < 0.001 versus Doxo Tyramine, \*p < 0.001 versus Vehicle by one-way ANOVA with post hoc Tukey's multiple comparison test. Approximately 30 cells were analyzed per condition in each experiment, and all the experiments were performed at least three times using three different animal or cell preparations. The GSSG/GSH ratio measurement, the total thiol estimation, and Western blot analyses were performed three times using three different animal preparations. Data are expressed as mean ± SEM. Integral blots are shown in Supplementary Figure S2. MAO, monoamine oxidase; NRVM, neonatal rat ventricular myocyte; SEM, standard error of the mean.

